source
- Novartis' DM1 drug del-desiran misses primary endpoint in Phase 3 HARBOR trialNovartis announced that its experimental therapy del-desiran did not improve muscle function in a pivotal Phase 3 study for myotonic dystrophy type 1 (DM1). The trial, called HARBOR, evaluated the…
- Moderna and Merck’s personalized mRNA cancer vaccine success spurs industry shift to faster, smaller-scale productionAfter mastering large‑scale mRNA manufacturing during the COVID‑19 pandemic, the sector is now turning its attention to delivering individualized vaccines to patients quickly. The recent clinical…